PRE-FUNDED COMMON SHARE PURCHASE WARRANT briacell therapeutics corp.BriaCell Therapeutics Corp. • March 13th, 2020 • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ________________, 20___ (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from BriaCell Therapeutics Corp., a British Columbia corporation (the “Company”), up to ______ Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITING AGREEMENT between BRIACELL THERAPEUTICS CORP. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters BRIACELL THERAPEUTICS CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • March 13th, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • New York
The undersigned, BriaCell Therapeutics Corp., a corporation formed under the laws of the Province of British Columbia (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of BriaCell Therapeutics Corp., (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
THE REGISTERED HOLDER OF THIS WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR...BriaCell Therapeutics Corp. • March 13th, 2020 • Pharmaceutical preparations
THIS WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS SIX MONTHS FROM THE EFFECTIVE DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING].
MASTER SERVICES AGREEMENTMaster Services Agreement • March 13th, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Texas
This MASTER SERVICES AGREEMENT (the “Agreement”) is made as of 2020 February 26 (the “Effective Date”), by and between BriaCell Therapeutics Corporation, with a principal place of business at 820 Heinz Avenue, Berkeley, CA 94710, together with its affiliates, (“Sponsor”) and Cancer Insight, LLC, with a place of business at 1305 East Houston Street, San Antonio, Texas 78205 (“Cancer Insight”). Sponsor and Cancer Insight are referred to herein individually as a “Party”, or collectively as the “Parties”.
Investigator Initiated Study Agreement (Drug)Investigator Initiated Study Agreement • March 13th, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Pennsylvania
This Agreement is entered into by and between Thomas Jefferson University, a Pennsylvania non-profit corporation, with an address at Office of Research Administration, 125 South 9th Street, Second Floor Sheridan Philadelphia, PA 19107, hereinafter called “Institution,” and BriaCell Therapeutics, a corporation with its principal office and place of business at 820 Heinz Avenue, Berkeley, CA 94710, hereinafter called “Sponsor.”
